Date: 18 November 2022
Learn more about the Emerging Antimicrobials and Diagnostics in AMR.
Date: 23 June 2022
‘Advancing Data Technologies to Corner AMR’ unlocks the potential of AI, IOT and Blockchain in fighting AMR.
Join Evotec at the ADCTA 2022 in June!
Learn more about the Advancing Data Technologies to Corner AMR.
Date: 16-20 May 2022
Location: Oxford, Alderly Park and Edinburgh, UK
Attending: Pia Thomas, Alastaire Parkes, Kirsty Holden
Our scientific program
Collaborating to drive promising antibacterial programs towards the clinic
Monday, May 16th | Oxford
Working together to combat AMR
Wednesday, May 18th | Alderly Park
If you wish to meet with us, get in touch via the form below, we will be happy to arrange a meeting.
Date: 8th-9th June 2022
Location: Congress Center Basel, Switzerland
Attendees: Rob Brown, Frederic Somny
Evotec will be exhibiting at BOS Basel, back in person this year. You can meet our experts at booth # 41 and discuss about your project needs in discovery and in the small molecules and biologics integrated CMC areas.
If you wish to meet with us in Basel or outside of the event, get in touch via the form below, we will be happy to arrange a meeting.
The dispensation of compounds in aqueous or DMSO solutions is an integral part of Evotec’s sample management processes. The company has the capability for the automated array of large numbers of samples between a large variety of different containers suitable for both, distribution or storage. Its extensive liquid handling resources cover the widest range of possible volumes.
High-volume systems can dispense and transfer from 1 uL to multi-milliliters to and from vials and plates, while mid-volume systems can dispense from 1 uL to 2 mL using 96, 384 and 1536 plates or racks (SBS - Society for Biomolecular Screening – formats).
As Evotec is striving towards the goal of getting drugs to patients faster, it is constantly seeking to improve the speed of screening cycles and data quality. To enable a step change in drug discovery research and development and to obtain results faster and even more accurately with very small sample sizes, Evotec recently invested in the so-called Acoustic Tubes technology in partnership with Brooks, Beckman and Titian. Acoustic sampling has revolutionised liquid handling and Evotec is using two different systems for acoustically dispensing volumes over 1 uL, or between 2.5 nl and 1 µl.
The technology is using ultrasonic acoustic energy, where energy focused just below the meniscus of a liquid sample ejects small droplets of liquid, enabling very small volumes to be transferred from source wells and precisely positioned onto a destination surface suspended above the ejection point. As a result, scientists can do more with less, handling multiple workflows and generating faster results without the restrictions of traditional tip-based liquid handling.
Moreover, this acoustic technology is combined with newly designed caps, a new de-capping and recapping technology hence creating the ability to store and access compounds long-term directly from the same tubes.
To evaluate the effects of acoustic labware use for long and short-term storage as well as the impact of freeze/thaw cycles and acoustic dispensing on compound integrity, Evotec has completed rigorous testing of the technology before adopting it.
The technology has a number of benefits. Most importantly, it speeds up screening cycles and improves the capacity for cherry-picking plate creation. Besides minimising compound consumption, it also works without disposable tips. This reduces waste, operating costs and eliminates the risk of cross-contamination between compounds. Moreover, its precision and speed leads to unsurpassed accuracy and repeatability of results, while maintaining sample integrity and viability during the transfer. All in all, it saves time, cost and resources, provides for highest possible precision, and increases the flexibility in transferring liquids at different positions and volumes.
Adoption of acoustic sampling technologies increases the flexibility of the compound library at Evotec and its partners and speeds up the throughput for assay-ready plate preparation while reducing the consumption of compounds. Evotec is offering direct access to this technology to its customers on demand.
Tags: Blog, Sample Management
Interesed in Evotec's Translational Molecular Patient Database?
In this presentation, first presented at our luncheon during German Biotechnology Days, focuses on:
View the presentation to learn more!
Date: 11 - 13 May 2022
Location: Coex, Soul and Virtual
Attendees: Tim Potter (In Person) and Nicholas Johnson (Virtually)
Read more about 2022 Bio Korea
Learn more about our activities for Deep Proteomics at Scale to Drive Biomarker Discovery.
To further boost Evotec’s high-throughput proteomics platform we have implemented the Proteograph™ platform from Seer, which enables automated and unbiased nanoparticle based protein enrichment for maximal proteomic insights.
Monoclonal antibodies (mAbs) have been a huge success story in the biopharmaceutical industry. They have changed the landscape of biologicals and offered therapies for previously untreatable diseases. Although mAbs have been on the market since the mid 1980s, they have become increasingly sophisticated over the past decades. This also holds true for the technologies enabling the identification, design, preclinical and manufacturing processes of monoclonal antibodies.
While the traditional hybridoma technology is still broadly used for the creation of mAbs, novel technologies such as immune antibody libraries or fully humanoid antibody libraries have emerged in recent years. Moreover, researchers can today leverage a range of powerful approaches to optimize the mAb creation process, e.g., high-throughput screening, state-of-the-art sequencing, AI / machine learning or analytics. This, in turn, speeds up the development cycle, allows for precise selection of the desired mAb properties and ultimately reduces failures of monoclonal antibodies at advanced development stages.
But how to choose from the vast range of technologies for antibody development? This challenge was discussed at Evotec´s recent Innovation Week in a session titled "Translate your idea into a product: AI -driven antibody discovery at Evotec".
The session covered Evotec´s capabilities for supporting all activities across the R&D continuum, i.e.
"In many cases, it is not the question of using either one or another technology," says Barbara Bachler-Konetzki, Group Leader In Vitro Pharmacology at Evotec. "Depending on the desired properties of the monoclonal antibody, combining several technologies will do the trick. Therefore, it is important to have access to a comprehensive repertoire of leading-edge, synergistic technologies."
For state-of-the-art monoclonal antibody development, Evotec has established a unique one-stop-shop from target identification to IND. This includes a broad technology platform as well as unparalleled expertise in drug development and even manufacturing, including latest advances in artificial intelligence and machine learning such as generative adversarial networks (GAN) to create synthetic realistic outcomes by machine learning (J.HAL).
The resulting integrated biologics platform is called J.DESIGN and integrates molecular, process and manufacturing design.
The example of Evotec´s internal SARS-CoV-2 campaign shows how its proprietary J.HAL technology can be used to identify antibodies effectively blocking the SARS-CoV-2 infection pathway by binding to SARS spike protein, effectively neutralizing the infectivity across several SARS-CoV-2 strains. The subsequent in silico sequence analysis informs about mAb properties and engineering opportunities to reach the desired properties re immunogenicity, stability etc. Further steps, e.g., sequence and stability optimization, improve manufacturability and yields or pharmacokinetics (PK).
For mAb development, Evotec pursues a translational approach, i.e., leveraging its extensive expertise in various therapeutic areas to facilitate the setup of disease-relevant biological assays. Among others, this allows for PK/PD characterization of biologics early in the R&D process as well as the prediction of downstream in vivo efficacy and demonstration of target engagement. Moreover, Evotec’s pre-clinical department offers the full range of in vitro and in vivo GLP and non-GLP pre-clinical evaluation studies to assess the safety profile of the drug candidate. In addition, Evotec has established several sophisticated manufacturing facilities worldwide to reduce the risk of downstream attrition and delay.
This unparalleled infrastructure and translational expertise put Evotec in a unique position to conduct leading-edge, integrated monoclonal antibody development programs all the way from target identification to manufacturing.
Tags: Blog, Videos & Webinars, Biologics